Caren Deardorf
CIK 1871152 · Chief Commercial Officer · last filed 2025-06-13
Caren Deardorf is a Chief Commercial Officer who has filed 14 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for CRNX, was dated Jun 13, 2025. Across all open-market trades the lifetime net is −$42.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $561.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$561.9K
2
14
-$42.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRNX | Director | 16,300 | $34.47 | $561.9K | $0 | 6 | 2025-06-13 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Chief Commercial Officer | 19,762 | $11.19 | $221.2K | -$42.0K | 8 | 2022-12-02 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-13 | CRNX | Grant (A) | +6,900 | $0 | EDGAR |
| 2024-06-11 | CRNX | Grant (A) | +3,400 | $0 | EDGAR |
| 2023-06-21 | CRNX | Grant (A) | +6,000 | $0 | EDGAR |
| 2022-12-02 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | +3,000 | $2.8K | EDGAR |
| 2022-08-01 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-21 | CRNX | Grant (A) | — | $0 | EDGAR |
| 2022-06-06 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | +3,000 | $3.0K | EDGAR |
| 2022-05-19 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-04-04 | CRNX | Grant (A) | — | $0 | EDGAR |
| 2022-03-14 | CRNX | Grant (A) | — | $0 | EDGAR |